<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939805</url>
  </required_header>
  <id_info>
    <org_study_id>20210121-2475</org_study_id>
    <nct_id>NCT04939805</nct_id>
  </id_info>
  <brief_title>CRP Apheresis in STEMI</brief_title>
  <official_title>Selective C-reactive Protein Apheresis in ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of&#xD;
      infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling&#xD;
      and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the&#xD;
      aim of reducing infarct size are therefore of great interest. Local and systemic inflammation&#xD;
      influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome.&#xD;
      C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects&#xD;
      the amount of irreversible myocardial tissue damage after acute myocardial infarction.&#xD;
&#xD;
      Objective: The main objectives of the current study are to investigate the efficacy of&#xD;
      selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to&#xD;
      standard of care for patients with acute STEMI treated with primary PCI.&#xD;
&#xD;
      Design: Investigator-initiated, prospective, randomized, open-label (outcome assessors&#xD;
      masked), controlled, multicenter, two group trial with a two-stage adaptive design.&#xD;
&#xD;
      Innovation: Selective CRP apheresis offers potential to decrease infarct size and&#xD;
      consequently improve outcome after PCI for STEMI. This is the first randomized trial&#xD;
      investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients.&#xD;
      In perspective, the study design allows furthermore to collect robust evidence for the design&#xD;
      of a definitive outcome study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy endpoint</measure>
    <time_frame>5 ± 2 days post PCI</time_frame>
    <description>Infarct size expressed as % of left ventricular myocardial mass (LVMM) as visualized by cardiac magnetic resonance (CMR) imaging at 5 ± 2 days post PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>during hospitalization for the index event</time_frame>
    <description>Adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) during hospitalization for the index event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality or hospitalization for heart failure within 12 months after randomization</measure>
    <time_frame>within 12 months after randomization</time_frame>
    <description>All-cause mortality or hospitalization for heart failure within 12 months after randomization (endpoint of interest with respect to the two-stage adaptive design)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR endpoints defined as: Left ventricular ejection fraction and microvascular obstruction and exploratory (intramyocardial hemorrhage, edema extent, myocardial salvage, native T1 mapping, strain)</measure>
    <time_frame>at baseline, 4 months and 12 months after PCI for STEMI</time_frame>
    <description>CMR endpoints will be assessed at baseline, 4 and 12 months CMR follow-up study and are defined according to the Journal of American College of Cardiology Scientific Expert Consensus document.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure within 12 months after randomization</measure>
    <time_frame>within 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality at 12 months</measure>
    <time_frame>within 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP concentrations</measure>
    <time_frame>during hospitalization for the index event</time_frame>
    <description>CRP concentrations during index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker concentrations of myocardial necrosis (enzymatic infarct size; high-sensitivity troponin T)</measure>
    <time_frame>at baseline, 4 months, 12 months post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker concentrations of hemodynamic stress (N-terminal pro-B-Type Natriuretic Peptide)</measure>
    <time_frame>at baseline, 4 months, 12 months post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function (eGFR)</measure>
    <time_frame>during hospitalization for the index event</time_frame>
    <description>as measured by the MDRD and CKD-EPI formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function (Cystatin C-based calculation of creatinine clearance)</measure>
    <time_frame>during hospitalization for the index event</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac autonomic function: Deceleration capacity of heart rate</measure>
    <time_frame>5 ± 2 days, 4 months, 12 months post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac autonomic function: Heart rate variability</measure>
    <time_frame>5 ± 2 days, 4 months, 12 months post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac autonomic function: Periodic repolarization dynamics</measure>
    <time_frame>5 ± 2 days, 4 months, 12 months post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac autonomic function: Baroreflex sensitivity</measure>
    <time_frame>5 ± 2 days, 4 months, 12 months post PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac autonomic function: Skin sympathetic nerve activity</measure>
    <time_frame>5 ± 2 days, 4 months, 12 months post PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>C-Reactive Protein</condition>
  <condition>Apheresis</condition>
  <condition>Myocardial Injury</condition>
  <arm_group>
    <arm_group_label>Selective CRP apheresis as an adjunct to standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care according to current guideline recommendations</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Selective CRP apheresis using the PentraSorb®-CRP system</intervention_name>
    <description>Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.</description>
    <arm_group_label>Selective CRP apheresis as an adjunct to standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of first acute STEMI in accordance with the European Society of Cardiology&#xD;
             (ESC) Guidelines for the management of acute myocardial infarction in patients&#xD;
             presenting with ST-segment elevation&#xD;
&#xD;
          2. Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12&#xD;
             hours prior to primary percutaneous coronary intervention (PCI)&#xD;
&#xD;
          3. CRP elevation of ≥7 mg/l measured between 6 to 16 hours after primary PCI&#xD;
&#xD;
          4. Eligible for primary PCI&#xD;
&#xD;
          5. Age ≥18 years&#xD;
&#xD;
          6. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior acute myocardial infarction, coronary artery bypass surgery or PCI.&#xD;
&#xD;
          2. Persistent hemodynamic instability (Killip class &gt;2 including cardiogenic shock) or&#xD;
             resuscitated cardiac arrest not allowing a CMR scan.&#xD;
&#xD;
          3. The patient is febrile (temperature &gt;38°C) or has experienced an acute infection with&#xD;
             fever in the last 14 days.&#xD;
&#xD;
          4. CRP &gt;15 mg/l at time of hospital admission.&#xD;
&#xD;
          5. Chronic inflammatory disease.&#xD;
&#xD;
          6. Known history of severe hepatic failure&#xD;
&#xD;
          7. Chronic kidney disease with a creatinine clearance &lt;30ml/min./1.73m²&#xD;
&#xD;
          8. Contraindication to CMR.&#xD;
&#xD;
          9. Pre-STEMI life expectancy of &lt;1 year&#xD;
&#xD;
         10. Participation in another interventional trial&#xD;
&#xD;
         11. Limited possibility to join the follow-up examinations (e.g. patient lives abroad)&#xD;
&#xD;
         12. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian J Reinstadler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian J Reinstadler, MD, PhD</last_name>
    <phone>+43 (0) 512 504 25665</phone>
    <email>sebastian.reinstadler@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivan Lechner, MD</last_name>
    <phone>+43 (0) 512 504 25665</phone>
    <email>ivan.lechner@tirol-kliniken.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic for Cardiology and Nephrology, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heiko Bugger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Heiko Bugger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathrin Eller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic of Internal Medicine III, Cardiology and Angiology. University Clinic of Internal Medicine IV, Nephrology and Hypertensiology. University Clinic of Radiology.</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian J Reinstadler, MD, PhD</last_name>
      <email>sebastian.reinstadler@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gert Klug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Kronbichler, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnes Mayr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Reindl, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Lechner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Tiller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magdalena Holzknecht, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Gauckler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Denicolò, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernhard Metzler, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axel Bauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gert Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elke Gizewski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic of Internal Medicine II, Paracelsus Medical University Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lukas J Motloch, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lukas J Motloch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans-Josef Feistritzer, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Holger Thiele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans-Josef Feistritzer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

